bluebird bio (BLUE) – General News
-
US FDA approves two gene therapies for sickle cell disease
-
Midday movers: Lululemon, Paramount and more
-
Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies
-
Express Scripts staking out million-dollar gene therapies
-
Wall Street ends higher with help from tech, energy
-
FDA panel backs Novartis' pioneering new cancer gene therapy
-
EU rapid drug approval plan worries some national agencies
Back to BLUE Stock Lookup